Publications
5891 Results
- Journal / Conference
- ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 107 oral
- Year
- 2026
- Research Committee(s)
- Breast
- Study Number(s)
- SWOG-8814
External Validation of the locked ArteraAI Breast MMAI model for Prognosis and Chemotherapy Benefit Prediction in Postmenopausal, Node-Positive, Hormone Receptor-Positive Breast Cancer Patients: Analysis of SWOG S8814
- Journal / Conference
-
ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il);
abs 2502 oral - Year
- 2026
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
DART (NCI/SWOG S1609): Comprehensive Results from Dual Checkpoint Inhibition with CTLA-4 and PD-1 Blockade in Rare Cancers
- Journal / Conference
- ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 2633 poster
- Year
- 2026
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Lung and/or Liver Metastases (NCI/SWOG S1609)
- Journal / Conference
- ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 12117 poster
- Year
- 2026
- Research Committee(s)
- Symptom Management and Survivorship
- Study Number(s)
- S1714
Post-Treatment Recovery Patterns among Patients with Early-Stage Cancer who Develop Taxane-Induced Peripheral Neuropathy (TIPN): SWOG S1714 (NCT03939481)
- Journal / Conference
- ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 12012 rapid oral
- Year
- 2026
- Research Committee(s)
- Symptom Management and Survivorship
- Study Number(s)
- S1714
Vitamin D insufficiency and risk of taxane-induced peripheral neuropathy: Results from SWOG S1714
- Journal / Conference
- ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs LBA5003 oral; J Clin Oncol 44, 2026 (suppl 17; abstr LBA5003) DOI: 10.1200/JCO.2026.44.17_suppl.LBA5003
- Year
- 2026
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- Study Number(s)
- S1823
First interim analysis of SWOG S1823: Operating characteristics of circulating microRNA 371a-3p (miR371) in predicting active germ cell malignancy (aGCM) in patients (pts) with early-stage testicular cancer
- Journal / Conference
- ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 11049 poster
- Year
- 2026
- Research Committee(s)
- Cancer Care Delivery
- Study Number(s)
- S1912CD
Baseline Financial and Credit Status of Participants Enrolled in SWOG S1912CD
- Journal / Conference
- ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 4012 rapid oral
- Year
- 2026
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- S2001
Randomized Phase II Trial of Olaparib + Pembrolizumab vs Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 (gBRCA1/2) Mutations: SWOG S2001
- Journal / Conference
- ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 521 poster
- Year
- 2026
- Research Committee(s)
- Symptom Management and Survivorship
- Study Number(s)
- S2010
Associations between self-efficacy and symptom burden in young women with breast cancer initiating endocrine therapy (ET) on SWOG S2010
- Journal / Conference
- ASCO Annual Meeting (May 29 - June 2, 2026, Chicago, Il); abs 2640 poster
- Year
- 2026
- Research Committee(s)
- Symptom Management and Survivorship
- Study Number(s)
- S2013